https://m2.mtmt.hu/ hun 2026-09-23 07:49 JournalArticle 35149394 VALIDATED true Department of Pharmacognosy, Semmelweis University, Budapest, 1085, Hungary College of Pharmaceutical Sciences, Zhejiang University, Zhejiang, Hangzhou, 310058, China Integrative Health and Environmental Analysis Research Laboratory, Department of Analytical Chemistry, Institute of Chemistry, Eötvös Loránd University, Budapest, 1117, Hungary Export Date: 30 April 2025; Cited By: 6; Correspondence Address: A. Nazli; Department of Pharmacognosy, Semmelweis University, Budapest, 1085, Hungary; email: nazli.adila@phd.semmelweis.hu; CODEN: EJMCA 0 false 2026-09-16T17:52:28.228+0000 2024-08-16T07:29:50.757+0000 2024-07-29T08:44:51.062+0000 true 10084172 Rácz Ákos /api/admin/10084172 Admin Rácz Ákos (SE_GYTK_Farmakognozia_Admin5_RÁ, admin) false 2025-04-30T09:02:10.971+0000 2024-08-05T10:22:43.104+0000 true 10062250 Molnár-Taga Márta /api/admin/10062250 Admin Molnár-Taga Márta (SE 4-es admin) true 10062250 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Összefoglaló cikk (Folyóiratcikk) 102 true 1134514 true 1 /api/category/1 Category Tudományos true 1 Nazli, Adila true true /api/journal/1507 REVIEWED EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 0223-5234 1768-3254 true false 1507 false 1507 true 0223-5234 1768-3254 Journal FOREIGN 276 116699 116699 32 2024 Funding 2042733 /api/funding/2042733 (SE250+ Excellence Scholarship for PhD Students) false true true true 2024 true true true false true false GOLD 2026-09-16 true https://doi.org/10.1016/j.ejmech.2024.116699 31 0 31 31 0 31 31 28 23 29 29 29 29 31 0 0 31 31 31 31 0 1 1 Folyóiratcikk Journal Article 24 30 Könyvrészlet Chapter in Book 25 1 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2024 0 2 2 2 2 2025 0 14 14 14 14 2026 0 15 15 15 15 Q1 false false false false 2024-08-01T11:19:09.387+0000 Analitikai Kémiai Tanszék (ELTE / TTK / KI); Farmakognóziai Intézet (SE / GYTK) 3 12 2 4 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 118442514 /api/authorship/118442514 Nazli, Adila ✉ [Nazli, Adila (farmakognózia), szerző] Farmakognóziai Intézet (SE / GYTK) 1 0.25 true false true Author 10087515 /api/author/10087515 Nazli Adila (farmakognózia) Nazli Adila true true Nazli Adila true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 118442515 /api/authorship/118442515 Irshad Khan, Muhammad Zafar 2 0.25 false false false Irshad Khan Muhammad Zafar true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 118442516 /api/authorship/118442516 Rácz, Ákos [Rácz, Ákos (molekula modellezés), szerző] Farmakognóziai Intézet (SE / GYTK) 3 0.25 false false false Author 10020499 /api/author/10020499 Rácz Ákos (molekula modellezés) Rácz Ákos true 10020499 true Rácz Ákos true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 118442517 /api/authorship/118442517 Béni, Szabolcs [Béni, Szabolcs (NMR-spektroszkópi...), szerző] Analitikai Kémiai Tanszék (ELTE / TTK / KI) 4 0.25 false true false Author 10001293 /api/author/10001293 Béni Szabolcs (NMR-spektroszkópia, analitikai kémia) Béni Szabolcs true 10001293 true Béni Szabolcs true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 26873602 /api/publicationidentifier/26873602 DOI: 10.1016/j.ejmech.2024.116699 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.1016/j.ejmech.2024.116699 https://doi.org/10.1016/j.ejmech.2024.116699 false true PublicationIdentifier 26934213 /api/publicationidentifier/26934213 WoS: 001285946300001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001285946300001 https://www.webofscience.com/wos/woscc/full-record/001285946300001 true true PublicationIdentifier 26904560 /api/publicationidentifier/26904560 Scopus: 85199955394 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85199955394 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85199955394 true true PublicationIdentifier 26934215 /api/publicationidentifier/26934215 PubMed: 39089000 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 39089000 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39089000&dopt=Abstract true true SjrRating 11456090 /api/sjrrating/11456090 sjr:Q1 (2024) Scopus - Drug Discovery EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 0223-5234 1768-3254 32 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 3002 /api/classificationexternal/3002 Scopus - Drug Discovery true 3002 true Q1 DIRECT true true Reference 56065641 /api/reference/56065641 1. Tewabe 2021: Targeted drug delivery-from magic bullet to nanomedicine: principles, challenges, and future perspectives., J Multidiscip Healthc, 14, p. 1711, DOI: 10.2147/JMDH.S313968 1 10.2147/JMDH.S313968 false true Reference 56065642 /api/reference/56065642 2. Rathnayake 2020: Targeted delivery of antibiotic therapy to inhibit Pseudomonas aeruginosa using lipid-coated mesoporous silica core-shell nanoassembly., ACS Appl Bio Mater, 3, p. 6708, DOI: 10.1021/acsabm.0c00622 2 10.1021/acsabm.0c00622 false true Reference 56065643 /api/reference/56065643 3. Mahato 2011: Prodrugs for improving tumor targetability and efficiency., Adv Drug Deliv Rev, 63, p. 659, DOI: 10.1016/j.addr.2011.02.002 3 10.1016/j.addr.2011.02.002 false true Reference 56065644 /api/reference/56065644 4. Souza 2019: Prodrugs for targeted cancer therapy., Expert Rev Anticancer Ther, 19, p. 483, DOI: 10.1080/14737140.2019.1615890 4 10.1080/14737140.2019.1615890 false true Reference 56065645 /api/reference/56065645 5. Zhao 2023: Doxorubicin prodrug-based nanomedicines for the treatment of cancer., Eur J Med Chem, 258, p. 115612, DOI: 10.1016/j.ejmech.2023.115612 5 10.1016/j.ejmech.2023.115612 false true Reference 56065646 /api/reference/56065646 6. Zhang 2017: Prodrug strategy for cancer cell-specific targeting: A recent overview., Eur J Med Chem, 139, p. 542, DOI: 10.1016/j.ejmech.2017.08.010 6 10.1016/j.ejmech.2017.08.010 false true Reference 56065647 /api/reference/56065647 7. Sanches 2019: Is prodrug design an approach to increase water solubility?., Int J Pharm, 568, p. 118498, DOI: 10.1016/j.ijpharm.2019.118498 7 10.1016/j.ijpharm.2019.118498 false true Reference 56065648 /api/reference/56065648 8. Nazli 2022: Strategies and progresses for enhancing targeted antibiotic delivery., Adv Drug Deliv Rev, 189, p. 114502, DOI: 10.1016/j.addr.2022.114502 8 10.1016/j.addr.2022.114502 false true Reference 56065649 /api/reference/56065649 9. Hunt 2000: Endogenous airway acidification: implications for asthma pathophysiology., Am J Respir Crit Care Med, 161, p. 694, DOI: 10.1164/ajrccm.161.3.9911005 9 10.1164/ajrccm.161.3.9911005 false true Reference 56065650 /api/reference/56065650 10. Simmonds 1992: Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease., Gastroenterology, 103, p. 186, DOI: 10.1016/0016-5085(92)91112-H 10 10.1016/0016-5085(92)91112-H false true Reference 56065651 /api/reference/56065651 11. Wang 2016: Stimuli-responsive dendrimers in drug delivery., Biomater Sci, 4, p. 375, DOI: 10.1039/C5BM00532A 11 10.1039/C5BM00532A false true Reference 56065652 /api/reference/56065652 12. Liu 2020: Stimulus-responsive nanomedicines for disease diagnosis and treatment., Int J Mol Sci, 21, p. 6380, DOI: 10.3390/ijms21176380 12 10.3390/ijms21176380 false true Reference 56065653 /api/reference/56065653 13. Hu 2014: Enzyme-responsive nanomaterials for controlled drug delivery., Nanoscale, 6, p. 12273, DOI: 10.1039/C4NR04249B 13 10.1039/C4NR04249B false true Reference 56065654 /api/reference/56065654 14. Pham 2020: Stimuli-responsive nanomaterials for application in antitumor therapy and drug delivery., Pharmaceutics, 12, p. 630, DOI: 10.3390/pharmaceutics12070630 14 10.3390/pharmaceutics12070630 false true Reference 56065655 /api/reference/56065655 15. Devnarain 2021: Intrinsic stimuli‐responsive nanocarriers for smart drug delivery of antibacterial agents-An in‐depth review of the last two decades., Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnology, 13, p. 1664 15 false true Reference 56065656 /api/reference/56065656 16. Doelle HW. Bacterial metabolism. 2nd ed. Massachusetts: Academic Press; 2014. 16 false true Reference 56065657 /api/reference/56065657 17. Deng 2021: Inflammation-responsive delivery systems for the treatment of chronic inflammatory diseases., Drug Deliv Transl Res, 11, p. 1475, DOI: 10.1007/s13346-021-00977-8 17 10.1007/s13346-021-00977-8 false true Reference 56065658 /api/reference/56065658 18. Raza 2019: Endogenous and exogenous stimuli-responsive drug delivery systems for programmed site-specific release., Molecules, 24, p. 1117, DOI: 10.3390/molecules24061117 18 10.3390/molecules24061117 false true Reference 56065659 /api/reference/56065659 19. Kanamala 2016: Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review., Biomaterials, 85, p. 152, DOI: 10.1016/j.biomaterials.2016.01.061 19 10.1016/j.biomaterials.2016.01.061 false true Reference 56065660 /api/reference/56065660 20. Liu 2014: pH-sensitive nano-systems for drug delivery in cancer therapy., Biotechnol Adv, 32, p. 693, DOI: 10.1016/j.biotechadv.2013.11.009 20 10.1016/j.biotechadv.2013.11.009 false true Reference 56065661 /api/reference/56065661 21. Bazban-Shotorbani 2017: Revisiting structure-property relationship of pH-responsive polymers for drug delivery applications., J Control Release, 253, p. 46, DOI: 10.1016/j.jconrel.2017.02.021 21 10.1016/j.jconrel.2017.02.021 false true Reference 56065662 /api/reference/56065662 22. Nguyen 2021: Recent trends in bioresponsive linker technologies of Prodrug-based self-assembling nanomaterials., Biomaterials, 275, p. 120955, DOI: 10.1016/j.biomaterials.2021.120955 22 10.1016/j.biomaterials.2021.120955 false true Reference 56065663 /api/reference/56065663 23. Ding 2022: Preparation and application of pH-responsive drug delivery systems., J Control Release, 348, p. 206, DOI: 10.1016/j.jconrel.2022.05.056 23 10.1016/j.jconrel.2022.05.056 false true Reference 56065664 /api/reference/56065664 24. Matsumoto K, Yanagi R, Oe Y. Recent advances in the synthesis of carboxylic acid esters. In: Georgiana IB, Gabriel LR, editors. Carboxylic acid-key role in life sciences. London: IntechOpen; 2018, p. 7-34., DOI: 10.5772/intechopen.74543 24 10.5772/intechopen.74543 false true Reference 56065665 /api/reference/56065665 25. Guo 2017: Facile access to multisensitive and self-healing hydrogels with reversible and dynamic boronic ester and disulfide linkages., Biomacromolecules, 18, p. 1356, DOI: 10.1021/acs.biomac.7b00089 25 10.1021/acs.biomac.7b00089 false true Reference 56065666 /api/reference/56065666 26. Ghosh 2015: Organic carbamates in drug design and medicinal chemistry., J Med Chem, 58, p. 2895, DOI: 10.1021/jm501371s 26 10.1021/jm501371s false true Reference 56065667 /api/reference/56065667 27. Knorr 2008: Acetal linked oligoethylenimines for use as pH-sensitive gene carriers., Bioconjug Chem, 19, p. 1625, DOI: 10.1021/bc8001858 27 10.1021/bc8001858 false true Reference 56065668 /api/reference/56065668 28. Chen 2021: Recent advances in prodrug-based nanoparticle therapeutics., Eur J Pharm Biopharm, 165, p. 219, DOI: 10.1016/j.ejpb.2021.04.025 28 10.1016/j.ejpb.2021.04.025 false true Reference 56065669 /api/reference/56065669 29. Shi 2020: pH-Sensitive nanoscale materials as robust drug delivery systems for cancer therapy., Chin Chem Lett, 31, p. 1345, DOI: 10.1016/j.cclet.2020.03.001 29 10.1016/j.cclet.2020.03.001 false true Reference 56065670 /api/reference/56065670 30. Damle 2003: Antibody-targeted chemotherapy with immunoconjugates of calicheamicin., Curr Opin Pharmacol, 3, p. 386, DOI: 10.1016/S1471-4892(03)00083-3 30 10.1016/S1471-4892(03)00083-3 false true Reference 56065671 /api/reference/56065671 31. Wang 2020: Disulfide based prodrugs for cancer therapy., RSC Adv, 10, p. 24397, DOI: 10.1039/D0RA04155F 31 10.1039/D0RA04155F false true Reference 56065672 /api/reference/56065672 32. Sheyi 2022: Linkers: an assurance for controlled delivery of antibody-drug conjugate., Pharmaceutics, 14, p. 396, DOI: 10.3390/pharmaceutics14020396 32 10.3390/pharmaceutics14020396 false true Reference 56065673 /api/reference/56065673 33. Jen 2018: FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-Positive acute myeloid leukemia FDA Approval summary: gemtuzumab ozogamicin., Clin Cancer Res, 24, p. 3242, DOI: 10.1158/1078-0432.CCR-17-3179 33 10.1158/1078-0432.CCR-17-3179 false true Reference 56065674 /api/reference/56065674 34. Mizutani 2019: An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells., Int J Hematol, 110, p. 490, DOI: 10.1007/s12185-019-02701-2 34 10.1007/s12185-019-02701-2 false true Reference 56065675 /api/reference/56065675 35. Kitson 2013: Antibody-drug conjugates (ADCs)-biotherapeutic bullets., Chem Today, 31, p. 30 35 false true Reference 56065676 /api/reference/56065676 36. Norsworthy 2018: FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33‐positive acute myeloid leukemia., The oncologist, 23, p. 1103, DOI: 10.1634/theoncologist.2017-0604 36 10.1634/theoncologist.2017-0604 false true Reference 56065677 /api/reference/56065677 37. Montesinos 2022: P579: A phase 4 study of fractionated gemtuzumab ozogamicin on qt interval and safety in patients with relapsed/refractory CD33-positive acute myeloid leukemia., HemaSphere, 6, p. 478, DOI: 10.1097/01.HS9.0000845204.22298.35 37 10.1097/01.HS9.0000845204.22298.35 false true Reference 56065678 /api/reference/56065678 38. Dan 2018: Antibody-drug conjugates for cancer therapy: chemistry to clinical implications., Pharmaceuticals, 11, p. 32, DOI: 10.3390/ph11020032 38 10.3390/ph11020032 false true Reference 56065679 /api/reference/56065679 39. Kantarjian 2016: Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia., N Engl J Med, 375, p. 740, DOI: 10.1056/NEJMoa1509277 39 10.1056/NEJMoa1509277 false true Reference 56065680 /api/reference/56065680 40. Lamb 2017: Inotuzumab ozogamicin: first global approval., Drugs, 77, p. 1603, DOI: 10.1007/s40265-017-0802-5 40 10.1007/s40265-017-0802-5 false true Reference 56065681 /api/reference/56065681 41. Tong 2021: An insight into FDA approved antibody-drug conjugates for cancer therapy., Molecules, 26, p. 5847, DOI: 10.3390/molecules26195847 41 10.3390/molecules26195847 false true Reference 56065682 /api/reference/56065682 42. Syed 2020: Sacituzumab govitecan: first approval., Drugs, 80, p. 1019, DOI: 10.1007/s40265-020-01337-5 42 10.1007/s40265-020-01337-5 false true Reference 56065683 /api/reference/56065683 43. Goldenberg 2019: Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan., MAbs, 11, p. 987, DOI: 10.1080/19420862.2019.1632115 43 10.1080/19420862.2019.1632115 false true Reference 56065684 /api/reference/56065684 44. Goldenberg 2015: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)., Oncotarget, 6, p. 22496, DOI: 10.18632/oncotarget.4318 44 10.18632/oncotarget.4318 false true Reference 56065685 /api/reference/56065685 45. Wahby 2021: FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer., Clin Cancer Res, 27, p. 1850, DOI: 10.1158/1078-0432.CCR-20-3119 45 10.1158/1078-0432.CCR-20-3119 false true Reference 56065686 /api/reference/56065686 46. Expanded Access for IMMU-132. https://clinicaltrials.gov/study/NCT04320693. 46 false true Reference 56065687 /api/reference/56065687 47. Najjar 2019: Successes, failures, and future prospects of prodrugs and their clinical impact., Expert Opin Drug Deliv, 14, p. 199, DOI: 10.1080/17460441.2019.1567487 47 10.1080/17460441.2019.1567487 false true Reference 56065688 /api/reference/56065688 48. Browning 2017: Drug delivery strategies for platinum-based chemotherapy., ACS nano, 11, p. 8560, DOI: 10.1021/acsnano.7b04092 48 10.1021/acsnano.7b04092 false true Reference 56065689 /api/reference/56065689 49. Hill 1982: Organo-platinum complexes as antitumor agents., Anticancer Res, 2, p. 173 49 false true Reference 56065690 /api/reference/56065690 50. Babu 2015: Nanoparticle-based cisplatin therapy for cancer., Ther. Deliv, 6, p. 115, DOI: 10.4155/tde.14.109 50 10.4155/tde.14.109 false true Reference 56065691 /api/reference/56065691 51. Choudhary D, Goykar H, Kalyane D, Sreeharsha N, Tekade RK. Prodrug design for improving the biopharmaceutical properties of therapeutic drugs. In: Erin HP, Pat G, editors. The future of pharmaceutical product development and research. Massachusetts: Academic press; 2020, p. 179-226., DOI: 10.1016/B978-0-12-814455-8.00006-2 51 10.1016/B978-0-12-814455-8.00006-2 false true Reference 56065692 /api/reference/56065692 52. Chandy 2013: Medicinal chemistry of amine prodrugs., Med Chem Drug Discov, 4, p. 108 52 false true Reference 56065693 /api/reference/56065693 53. Ji 2020: Cranberry products for the prevention of catheter-associated urinary tract infections., Curr Bladder Dysfunct Rep, 15, p. 303, DOI: 10.1007/s11884-020-00610-3 53 10.1007/s11884-020-00610-3 false true Reference 56065694 /api/reference/56065694 54. Lee 2005: Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue., Antimicrob Agents Chemother, 49, p. 1898, DOI: 10.1128/AAC.49.5.1898-1906.2005 54 10.1128/AAC.49.5.1898-1906.2005 false true Reference 56065695 /api/reference/56065695 55. Cundy 1998: Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R) 2-(phosphonomethoxy) propyl] adenine (PMPA) in dogs., Antimicrob Agents Chemother, 42, p. 687, DOI: 10.1128/AAC.42.3.687 55 10.1128/AAC.42.3.687 false true Reference 56065696 /api/reference/56065696 56. Rautio 2017: Prodrugs-Recent approvals and a glimpse of the pipeline., Eur J Pharm Sci, 109, p. 146, DOI: 10.1016/j.ejps.2017.08.002 56 10.1016/j.ejps.2017.08.002 false true Reference 56065697 /api/reference/56065697 57. Dejesus 2018: Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate-to a tenofovir alafenamide-based regimen through 96 weeks of treatment., AIDS Res. Hum, 34, p. 337, DOI: 10.1089/aid.2017.0203 57 10.1089/aid.2017.0203 false true Reference 56065698 /api/reference/56065698 58. De Clercq 2016: Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)., Biochem Pharmacol, 119, p. 1, DOI: 10.1016/j.bcp.2016.04.015 58 10.1016/j.bcp.2016.04.015 false true Reference 56065699 /api/reference/56065699 59. Rautio 2018: The expanding role of prodrugs in contemporary drug design and development., Nat Rev Drug Discov, 17, p. 559, DOI: 10.1038/nrd.2018.46 59 10.1038/nrd.2018.46 false true Reference 56065700 /api/reference/56065700 60. Shin 2004: Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors., J Am Chem Soc, 126, p. 7800, DOI: 10.1021/ja049607w 60 10.1021/ja049607w false true Reference 56065701 /api/reference/56065701 61. Parise 2010: Prodrugs available on the Brazilian pharmaceutical market and their corresponding bioactivation pathways., Braz J Pharm Sci, 46, p. 393, DOI: 10.1590/S1984-82502010000300003 61 10.1590/S1984-82502010000300003 false true Reference 56065702 /api/reference/56065702 62. Rouaz-El-Hajoui 2023: Formulation of Omeprazole in the pediatric population: a review., J Pharm Sci Drug Discov, 2, p. 1 62 false true Reference 56065703 /api/reference/56065703 63. Unger 2007: Phase I and pharmacokinetic study of the (6-maleimidocaproyl) hydrazone derivative of doxorubicin., Clin Cancer Res, 13, p. 4858, DOI: 10.1158/1078-0432.CCR-06-2776 63 10.1158/1078-0432.CCR-06-2776 false true Reference 56065704 /api/reference/56065704 64. Gong 2018: Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas., Drug Des Devel Ther, 12, p. 777, DOI: 10.2147/DDDT.S140638 64 10.2147/DDDT.S140638 false true Reference 56065705 /api/reference/56065705 65. Chawla 2017: Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas., J Clin Oncol, 35, p. 1, DOI: 10.1200/JCO.2017.35.15_suppl.11000 65 10.1200/JCO.2017.35.15_suppl.11000 false true Reference 56065706 /api/reference/56065706 66. Kasper 2019: The challenge of finding new therapeutic avenues in soft tissue sarcomas., Clinical sarcoma research, 9, p. 1, DOI: 10.1186/s13569-019-0115-4 66 10.1186/s13569-019-0115-4 false true Reference 56065707 /api/reference/56065707 67. Groves 2016: Phase 2 study of aldoxorubicin in relapsed glioblastoma., Am Soc Clin Oncol, 34, p. 1 67 false true Reference 56065708 /api/reference/56065708 68. Parsons 2016: Treatment of HIV-associated Kaposi's sarcoma with aldoxorubicin., Am Soc Clin Oncol, 33, p. 1 68 false true Reference 56065709 /api/reference/56065709 69. Robak 2016: Management of multiple myeloma with second-generation antibody-drug conjugates., BioDrugs, 30, p. 87, DOI: 10.1007/s40259-016-0165-6 69 10.1007/s40259-016-0165-6 false true Reference 56065710 /api/reference/56065710 70. Nanna AR, Roush WR, Rader C. Chemical assembly of antibody-drug conjugates, in next generation antibody drug conjugates (ADCs) and immunotoxins. Ulf Grawunder, Stefan Barth, editors. New York:Springer; 2017, p. 33-39., DOI: 10.1007/978-3-319-46877-8_1 70 10.1007/978-3-319-46877-8_1 false true Reference 56065711 /api/reference/56065711 71. Robak 2014: Current phase II antibody-drug conjugates for the treatment of lymphoid malignancies., Expert Opin Investig Drugs, 23, p. 911, DOI: 10.1517/13543784.2014.908184 71 10.1517/13543784.2014.908184 false true Reference 56065712 /api/reference/56065712 72. McMillan 2021: Antibody-drug conjugates for multiple myeloma., Expert Opin Biol Ther, 21, p. 889, DOI: 10.1080/14712598.2020.1802422 72 10.1080/14712598.2020.1802422 false true Reference 56065713 /api/reference/56065713 73. Abramson 2018: Monoclonal antibodies for the treatment of multiple myeloma: an update., Int J Mol Sci, 19, p. 3924, DOI: 10.3390/ijms19123924 73 10.3390/ijms19123924 false true Reference 56065714 /api/reference/56065714 74. Zheng 2021: An overview of polymeric nanomicelles in clinical trials and on the market., Chin Chem Lett, 32, p. 243, DOI: 10.1016/j.cclet.2020.11.029 74 10.1016/j.cclet.2020.11.029 false true Reference 56065715 /api/reference/56065715 75. Mukai 2017: A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors., Investig. New Drugs, 35, p. 307, DOI: 10.1007/s10637-016-0422-z 75 10.1007/s10637-016-0422-z false true Reference 56065716 /api/reference/56065716 76. Harada 2011: Improved anti‐tumor activity of stabilized anthracycline polymeric micelle formulation, NC‐6300., Cancer Sci, 102, p. 192, DOI: 10.1111/j.1349-7006.2010.01745.x 76 10.1111/j.1349-7006.2010.01745.x false true Reference 56065717 /api/reference/56065717 77. Chawla 2020: A phase 1b dose escalation trial of NC-6300 (nanoparticle epirubicin) in patients with advanced solid tumors or advanced, metastatic, or unresectable soft-tissue sarcoma., Clin Cancer Res, 26, p. 4225, DOI: 10.1158/1078-0432.CCR-20-0591 77 10.1158/1078-0432.CCR-20-0591 false true Reference 56065718 /api/reference/56065718 78. Rezai 2007: Preclinical study of the transport, intracellular distribution and metabolism of ProLindacTM, a novel diaminocyclohexane-platinum (DACH-Pt) tumor-targeting drug delivery system., Cancer Res, 67, p. 3198 78 false true Reference 56065719 /api/reference/56065719 79. Nowotnik 2009: ProLindac™(AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic., Adv Drug Deliv Rev, 61, p. 1214, DOI: 10.1016/j.addr.2009.06.004 79 10.1016/j.addr.2009.06.004 false true Reference 56065720 /api/reference/56065720 80. Howell SB. The design and development of the tumor-targeting nanopolymer dach platinum conjugate AP5346 (Prolindac™). Andrea B, Roberto L, Franco M, Stephen BH, editors.Platinum and other heavy metal compounds in cancer chemotherapy. New York: Springer; 2009, p. 33-39., DOI: 10.1007/978-1-60327-459-3_5 80 10.1007/978-1-60327-459-3_5 false true Reference 56065721 /api/reference/56065721 81. Poursharifi 2018: Nano-based systems and biomacromolecules as carriers for metallodrugs in anticancer therapy., Inorganics, 7, p. 2, DOI: 10.3390/inorganics7010002 81 10.3390/inorganics7010002 false true Reference 56065722 /api/reference/56065722 82. Koester 2016: DK049, a novel acid-sensitive prodrug of gemcitabine: design, in vitro properties and in vivo efficacy., Cancer Res, 76, p. 2061, DOI: 10.1158/1538-7445.AM2016-2061 82 10.1158/1538-7445.AM2016-2061 false true Reference 56065723 /api/reference/56065723 83. CytRx nominates next clinical drug candidate DK049. https://www.prnewswire.com/news-releases/cytrx-nominates-next-clinical-drug-candidate-dk049-300188329.html. 83 false true Reference 56065724 /api/reference/56065724 84. Delahousse 2019: Prodrugs as drug delivery system in oncology., Cancer Chemother Pharmacol, 84, p. 937, DOI: 10.1007/s00280-019-03906-2 84 10.1007/s00280-019-03906-2 false true Reference 56065725 /api/reference/56065725 85. Patel 2016: Hypoxic tumor microenvironment: Opportunities to develop targeted therapies., Biotechnol Adv, 34, p. 803, DOI: 10.1016/j.biotechadv.2016.04.005 85 10.1016/j.biotechadv.2016.04.005 false true Reference 56065726 /api/reference/56065726 86. Li 2021: Intelligent stimuli-responsive nano immunomodulators for cancer immunotherapy., Chem Sci, 12, p. 3130, DOI: 10.1039/D0SC06557A 86 10.1039/D0SC06557A false true Reference 56065727 /api/reference/56065727 87. Mu 2020: Acid-sensitive PEGylated paclitaxel prodrug nanoparticles for cancer therapy: Effect of PEG length on antitumor efficacy., J Control Release, 326, p. 265, DOI: 10.1016/j.jconrel.2020.07.022 87 10.1016/j.jconrel.2020.07.022 false true Reference 56065728 /api/reference/56065728 88. Gu 2013: Acetal-linked paclitaxel prodrug micellar nanoparticles as a versatile and potent platform for cancer therapy., Biomacromolecules, 14, p. 2772, DOI: 10.1021/bm400615n 88 10.1021/bm400615n false true Reference 56065729 /api/reference/56065729 89. Feng 2017: Schiff base bond-linked polysaccharide–doxorubicin conjugate for upregulated cancer therapy., Mater Sci Eng C, 76, p. 1121, DOI: 10.1016/j.msec.2017.03.201 89 10.1016/j.msec.2017.03.201 false true Reference 56065730 /api/reference/56065730 90. Li 2016: Self-targeted polysaccharide prodrug suppresses orthotopic hepatoma., Mol Pharmaceutics, 13, p. 4231, DOI: 10.1021/acs.molpharmaceut.6b00747 90 10.1021/acs.molpharmaceut.6b00747 false true Reference 56065731 /api/reference/56065731 91. Hochdorffer 2012: Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix., J Med Chem, 55, p. 7502, DOI: 10.1021/jm300493m 91 10.1021/jm300493m false true Reference 56065732 /api/reference/56065732 92. Guo 2013: pH-triggered intracellular release from actively targeting polymer micelles., Biomaterials, 34, p. 4544, DOI: 10.1016/j.biomaterials.2013.02.071 92 10.1016/j.biomaterials.2013.02.071 false true Reference 56065733 /api/reference/56065733 93. Sun 2015: pH‐responsive reversible PEGylation improves performance of antineoplastic agent., Adv Healthc Mater, 4, p. 844, DOI: 10.1002/adhm.201400736 93 10.1002/adhm.201400736 false true Reference 56065734 /api/reference/56065734 94. Bae 2005: Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy., Bioconjug Chem, 16, p. 122, DOI: 10.1021/bc0498166 94 10.1021/bc0498166 false true Reference 56065735 /api/reference/56065735 95. Zhu 2018: Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy., Nanoscale, 10, p. 18387, DOI: 10.1039/C8NR03899F 95 10.1039/C8NR03899F false true Reference 56065736 /api/reference/56065736 96. Liu 2021: Acid-sensitive PEGylated cabazitaxel prodrugs for antitumor therapy., Chin Chem Lett, 32, p. 1751, DOI: 10.1016/j.cclet.2020.12.008 96 10.1016/j.cclet.2020.12.008 false true Reference 56065737 /api/reference/56065737 97. Liu 2017: A pH-responsive prodrug delivery system of 10-HCPT for controlled release and tumor targeting., Int J Nanomed, 12, p. 2227, DOI: 10.2147/IJN.S125849 97 10.2147/IJN.S125849 false true Reference 56065738 /api/reference/56065738 98. Qu 2019: Redox/pH dual-stimuli responsive camptothecin prodrug nanogels for “on-demand” drug delivery., J Control Release, 296, p. 93, DOI: 10.1016/j.jconrel.2019.01.016 98 10.1016/j.jconrel.2019.01.016 false true Reference 56065739 /api/reference/56065739 99. Zhang 2016: A pH-sensitive nanosystem based on carboxymethyl chitosan for tumor-targeted delivery of daunorubicin., J Biomed Nanotechnol, 12, p. 1688, DOI: 10.1166/jbn.2016.2278 99 10.1166/jbn.2016.2278 false true Reference 56065740 /api/reference/56065740 100. Zheng 2021: Construction of a phenylboronic acid-functionalized nano-prodrug for pH-responsive emodin delivery and antibacterial activity., ACS omega, 6, p. 8672, DOI: 10.1021/acsomega.1c00606 100 10.1021/acsomega.1c00606 false true Reference 56065741 /api/reference/56065741 101. Yang 2021: Dynamic precise dual-drug-backboned nano-prodrugs for selective chemotherapy., Acta Biomater, 129, p. 209, DOI: 10.1016/j.actbio.2021.05.013 101 10.1016/j.actbio.2021.05.013 false true Reference 56065742 /api/reference/56065742 102. Yu 2020: Dually enzyme-and acid-triggered self-immolative ketal glycoside nanoparticles for effective cancer prodrug monotherapy., Nano Lett, 20, p. 5465, DOI: 10.1021/acs.nanolett.0c01973 102 10.1021/acs.nanolett.0c01973 false true Reference 56065743 /api/reference/56065743 103. Zhong 2020: Acid-triggered release of native gemcitabine conjugated in polyketal nanoparticles for enhanced anticancer therapy., Biomacromolecules, 21, p. 803, DOI: 10.1021/acs.biomac.9b01493 103 10.1021/acs.biomac.9b01493 false true Reference 56065744 /api/reference/56065744 104. Binauld 2012: pH-Triggered release of platinum drugs conjugated to micelles via an acid-cleavable linker., Macromolecules, 45, p. 6989, DOI: 10.1021/ma3012812 104 10.1021/ma3012812 false true Reference 56065745 /api/reference/56065745 105. Zhang 2020: pH-Sensitive betulinic acid polymer prodrug nanoparticles for efficient and targeted cancer cells treatment., Int J Polym Mater, 69, p. 659, DOI: 10.1080/00914037.2019.1596916 105 10.1080/00914037.2019.1596916 false true Reference 56065746 /api/reference/56065746 106. Mura 2013: Stimuli-responsive nanocarriers for drug delivery., Nat. Mater, 12, p. 991, DOI: 10.1038/nmat3776 106 10.1038/nmat3776 false true Reference 56065747 /api/reference/56065747 107. Chen 2019: A dual pH-sensitive liposomal system with charge-reversal and NO generation for overcoming multidrug resistance in cancer., Nanoscale, 11, p. 3814, DOI: 10.1039/C8NR06218H 107 10.1039/C8NR06218H false true Reference 56065748 /api/reference/56065748 108. Luo 2019: pH-responsive stearic acid-O-carboxymethyl chitosan assemblies as carriers delivering small molecular drug for chemotherapy., Mater Sci Eng C, 105, p. 110107, DOI: 10.1016/j.msec.2019.110107 108 10.1016/j.msec.2019.110107 false true Reference 56065749 /api/reference/56065749 109. Zhai 2017: Acetal-linked paclitaxel polymeric prodrug based on functionalized mPEG-PCL diblock polymer for pH-triggered drug delivery., Polymers, 9, p. 698, DOI: 10.3390/polym9120698 109 10.3390/polym9120698 false true Reference 56065750 /api/reference/56065750 110. Sun 2015: Recent advance on mesoporous silica nanoparticles-based controlled release system: intelligent switches open up new horizon., Nanomaterials, 5, p. 2019, DOI: 10.3390/nano5042019 110 10.3390/nano5042019 false true Reference 56065751 /api/reference/56065751 111. Wang 2016: Synthesis of pH-sensitive, water-soluble paclitaxel prodrugs based on norbornene-functional polylactide by copper-free click chemistry., Int J Polym Mater, 65, p. 789, DOI: 10.1080/00914037.2016.1171219 111 10.1080/00914037.2016.1171219 false true Reference 56065752 /api/reference/56065752 112. Zhang 2019: Poly (cystine–PCL) based pH/redox dual-responsive nanocarriers for enhanced tumor therapy., Biomater Sci, 7, p. 1962, DOI: 10.1039/C9BM00009G 112 10.1039/C9BM00009G false true Reference 56065753 /api/reference/56065753 113. Liu 2010: Novel pH-sensitive chitosan-derived micelles loaded with paclitaxel., Carbohydr Polym, 82, p. 432, DOI: 10.1016/j.carbpol.2010.04.084 113 10.1016/j.carbpol.2010.04.084 false true Reference 56065754 /api/reference/56065754 114. Narayan 2021: Chitosan-glucuronic acid conjugate coated mesoporous silica nanoparticles: A smart pH-responsive and receptor-targeted system for colorectal cancer therapy., Carbohydr Polym, 261, p. 117893, DOI: 10.1016/j.carbpol.2021.117893 114 10.1016/j.carbpol.2021.117893 false true Reference 56065755 /api/reference/56065755 115. Sedláček O, Hrubý M, Studenovský M, Větvička D, Svoboda J, Kaňková D, Kovář J, Ulbrich K. Polymer conjugates of acridine-type anticancer drugs with pH-controlled activation. Bioorg Med Chem2012;20:4056-4063., DOI: 10.1016/j.bmc.2012.05.007 115 10.1016/j.bmc.2012.05.007 false true Reference 56065756 /api/reference/56065756 116. Zhang 2020: The design and synthesis of dextran-doxorubicin prodrug-based pH-sensitive drug delivery system for improving chemotherapy efficacy., Asian J Pharm Sci, 15, p. 605, DOI: 10.1016/j.ajps.2019.10.001 116 10.1016/j.ajps.2019.10.001 false true Reference 56065757 /api/reference/56065757 117. Low 2014: Bone-targeted acid-sensitive doxorubicin conjugate micelles as potential osteosarcoma therapeutics., Bioconjug Chem, 25, p. 2012, DOI: 10.1021/bc500392x 117 10.1021/bc500392x false true Reference 56065758 /api/reference/56065758 118. Ma 2018: Acid-activatable doxorubicin prodrug micelles with folate-targeted and ultra-high drug loading features for efficient antitumor drug delivery., J Mater Sci, 53, p. 892, DOI: 10.1007/s10853-017-1546-z 118 10.1007/s10853-017-1546-z false true Reference 56065759 /api/reference/56065759 119. Li 2014: A pH-responsive prodrug for real-time drug release monitoring and targeted cancer therapy., Chem Commun, 50, p. 11852, DOI: 10.1039/C4CC05008H 119 10.1039/C4CC05008H false true Reference 56065760 /api/reference/56065760 120. Kim 2012: Synthesis and evaluation of biotin-conjugated pH-responsive polymeric micelles as drug carriers., Int J Pharm, 427, p. 435, DOI: 10.1016/j.ijpharm.2012.01.034 120 10.1016/j.ijpharm.2012.01.034 false true Reference 56065761 /api/reference/56065761 121. Fleige 2014: pH-responsive dendritic core–multishell nanocarriers., J Control Release, 185, p. 99, DOI: 10.1016/j.jconrel.2014.04.019 121 10.1016/j.jconrel.2014.04.019 false true Reference 56065762 /api/reference/56065762 122. Zhang 2017: Facile preparation of pH/reduction dual-responsive prodrug microspheres with high drug content for tumor intracellular triggered release of DOX., React Funct Polym, 116, p. 24, DOI: 10.1016/j.reactfunctpolym.2017.05.002 122 10.1016/j.reactfunctpolym.2017.05.002 false true Reference 56065763 /api/reference/56065763 123. Lin 2016: Integrated self-assembling drug delivery system possessing dual responsive and active targeting for orthotopic ovarian cancer theranostics., Biomaterials, 90, p. 12, DOI: 10.1016/j.biomaterials.2016.03.005 123 10.1016/j.biomaterials.2016.03.005 false true Reference 56065764 /api/reference/56065764 124. Chytil 2006: Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification., J Control Release, 115, p. 26, DOI: 10.1016/j.jconrel.2006.06.028 124 10.1016/j.jconrel.2006.06.028 false true Reference 56065765 /api/reference/56065765 125. Hu 2009: Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles., Biomaterials, 30, p. 6955, DOI: 10.1016/j.biomaterials.2009.09.008 125 10.1016/j.biomaterials.2009.09.008 false true Reference 56065766 /api/reference/56065766 126. Zhang 2014: A facile approach for dual-responsive prodrug nanogels based on dendritic polyglycerols with minimal leaching., J Control Release, 174, p. 209, DOI: 10.1016/j.jconrel.2013.11.005 126 10.1016/j.jconrel.2013.11.005 false true Reference 56065767 /api/reference/56065767 127. Pourjavadi 2020: pH and thermal dual-responsive poly (NIPAM-co-GMA)-coated magnetic nanoparticles via surface-initiated RAFT polymerization for controlled drug delivery., Mater Sci Eng C, 108, p. 110418, DOI: 10.1016/j.msec.2019.110418 127 10.1016/j.msec.2019.110418 false true Reference 56065768 /api/reference/56065768 128. Guan 2014: Cyclic RGD targeting nanoparticles with pH sensitive polymer-drug conjugates for effective treatment of melanoma., RSC Adv, 4, p. 55187, DOI: 10.1039/C4RA08537J 128 10.1039/C4RA08537J false true Reference 56065769 /api/reference/56065769 129. Yuan 2019: Sharp pH-responsive mannose prodrug polypeptide nanoparticles encapsulating a photosensitizer for enhanced near infrared imaging-guided photodynamic therapy., J Mater Chem B, 7, p. 6770, DOI: 10.1039/C9TB01527B 129 10.1039/C9TB01527B false true Reference 56065770 /api/reference/56065770 130. Zhang 2015: Boronate cross‐linked ATP‐and pH‐Responsive nanogels for intracellular delivery of anticancer drugs., Adv Healthc Mater, 4, p. 585, DOI: 10.1002/adhm.201400550 130 10.1002/adhm.201400550 false true Reference 56065771 /api/reference/56065771 131. Li 2017: pH-Sensitive mesoporous silica nanoparticles anticancer prodrugs for sustained release of ursolic acid and the enhanced anti-cancer efficacy for hepatocellular carcinoma cancer., Eur J Pharm Sci, 96, p. 456, DOI: 10.1016/j.ejps.2016.10.019 131 10.1016/j.ejps.2016.10.019 false true Reference 56065772 /api/reference/56065772 132. Özsoy 2021: A protein-sulfosalicylic acid/boswellic acids@ metal–organic framework nanocomposite as anticancer drug delivery system., Colloids Surf B Biointerfaces, 204, p. 111788, DOI: 10.1016/j.colsurfb.2021.111788 132 10.1016/j.colsurfb.2021.111788 false true Reference 56065773 /api/reference/56065773 133. Cyphert 2017: Erythromycin modification that improves its acidic stability while optimizing it for local drug delivery., Antibiotics, 6, p. 11, DOI: 10.3390/antibiotics6020011 133 10.3390/antibiotics6020011 false true Reference 56065774 /api/reference/56065774 134. Yin 2021: Ciprofloxacin conjugated gold nanorods with pH induced surface charge transformable activities to combat drug resistant bacteria and their biofilms., Mater Sci Eng C, 128, p. 112292, DOI: 10.1016/j.msec.2021.112292 134 10.1016/j.msec.2021.112292 false true Reference 56065775 /api/reference/56065775 135. Sedghizadeh 2017: Design, synthesis, and antimicrobial evaluation of a novel bone-targeting bisphosphonate-ciprofloxacin conjugate for the treatment of osteomyelitis biofilms., J Med Chem, 60, p. 2326, DOI: 10.1021/acs.jmedchem.6b01615 135 10.1021/acs.jmedchem.6b01615 false true Reference 56065776 /api/reference/56065776 136. Wang 2021: Bacterial infection microenvironment sensitive prodrug micelles with enhanced photodynamic activities for infection control., Colloids Interface Sci Commun, 40, p. 100354, DOI: 10.1016/j.colcom.2020.100354 136 10.1016/j.colcom.2020.100354 false true Reference 56065777 /api/reference/56065777 137. Semiramoth 2012: Self-assembled squalenoylated penicillin bioconjugates: an original approach for the treatment of intracellular infections., ACS nano, 6, p. 3820, DOI: 10.1021/nn204928v 137 10.1021/nn204928v false true Reference 56065778 /api/reference/56065778 138. Kalhapure 2017: pH-responsive chitosan nanoparticles from a novel twin-chain anionic amphiphile for controlled and targeted delivery of vancomycin., Colloids Surf B Biointerfaces, 158, p. 650, DOI: 10.1016/j.colsurfb.2017.07.049 138 10.1016/j.colsurfb.2017.07.049 false true Reference 56065779 /api/reference/56065779 139. Jadhav 2018: Novel lipids with three C18-fatty acid chains and an amino acid head group for pH-responsive and sustained antibiotic delivery., Chem Phys Lipids, 212, p. 12, DOI: 10.1016/j.chemphyslip.2017.12.007 139 10.1016/j.chemphyslip.2017.12.007 false true Reference 56065780 /api/reference/56065780 140. Mhule 2018: Synthesis of an oleic acid based pH-responsive lipid and its application in nanodelivery of vancomycin., Int J Pharm, 550, p. 149, DOI: 10.1016/j.ijpharm.2018.08.025 140 10.1016/j.ijpharm.2018.08.025 false true Reference 56065781 /api/reference/56065781 141. Sonawane 2020: AB2-type amphiphilic block copolymer containing a pH-cleavable hydrazone linkage for targeted antibiotic delivery., Int J Pharm, 575, p. 118948, DOI: 10.1016/j.ijpharm.2019.118948 141 10.1016/j.ijpharm.2019.118948 false true Reference 56065782 /api/reference/56065782 142. Dou 2020: Bioresponsive drug delivery systems for the treatment of inflammatory diseases., J Control Release, 327, p. 641, DOI: 10.1016/j.jconrel.2020.09.008 142 10.1016/j.jconrel.2020.09.008 false true Reference 56065783 /api/reference/56065783 143. Funk 2011: Development of a novel polyethylene glycol-corticosteroid-conjugate with an acid-cleavable linker., J Drug Targeting, 19, p. 434, DOI: 10.3109/1061186X.2010.504271 143 10.3109/1061186X.2010.504271 false true Reference 56065784 /api/reference/56065784 144. Wang 2007: Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis., Arthritis Res Ther, 9, p. 1, DOI: 10.1186/ar2106 144 10.1186/ar2106 false true Reference 56065785 /api/reference/56065785 145. Zhang 2018: Bioresponsive nanoparticles targeted to infectious microenvironments for sepsis management., Adv Mater, 30, p. 1803618, DOI: 10.1002/adma.201803618 145 10.1002/adma.201803618 false true Reference 56065786 /api/reference/56065786 146. Singh 2019: Dual bioresponsive antibiotic and quorum sensing inhibitor combination nanoparticles for treatment of Pseudomonas aeruginosa biofilms in vitro and ex vivo., Biomater Sci, 7, p. 4099, DOI: 10.1039/C9BM00773C 146 10.1039/C9BM00773C false true Reference 56065787 /api/reference/56065787 147. Munir 2019: Controllably biodegradable hydroxyapatite nanostructures for cefazolin delivery against antibacterial resistance., ACS Omega, 4, p. 7524, DOI: 10.1021/acsomega.9b00541 147 10.1021/acsomega.9b00541 false true Reference 56065788 /api/reference/56065788 148. Min 2019: pH-Responsive mineralized nanoparticles for bacteria-triggered topical release of antibiotics., J Ind Eng Chem, 71, p. 210, DOI: 10.1016/j.jiec.2018.11.027 148 10.1016/j.jiec.2018.11.027 false true Reference 56065789 /api/reference/56065789 149. Pourjavadi 2014: Mesoporous silica nanoparticles (MCM-41) coated PEGylated chitosan as a pH-responsive nanocarrier for triggered release of erythromycin., Int J Polym Mater, 63, p. 692, DOI: 10.1080/00914037.2013.862534 149 10.1080/00914037.2013.862534 false true Reference 56065790 /api/reference/56065790 150. Lutwyche 1998: Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes., Antimicrob Agents Chemother, 42, p. 2511, DOI: 10.1128/AAC.42.10.2511 150 10.1128/AAC.42.10.2511 false true Reference 56065791 /api/reference/56065791 151. Pavlukhina 2014: Small-molecule-hosting nanocomposite films with multiple bacteria-triggered responses., NPG Asia Mater, 6, p. 121, DOI: 10.1038/am.2014.63 151 10.1038/am.2014.63 false true Reference 56065792 /api/reference/56065792 152. Anirudhan 2018: Novel pH sensitive dual drug loaded-gelatin methacrylate/methacrylic acid hydrogel for the controlled release of antibiotics., Int J Biol Macromol, 110, p. 167, DOI: 10.1016/j.ijbiomac.2018.01.220 152 10.1016/j.ijbiomac.2018.01.220 false true Reference 56065793 /api/reference/56065793 153. Su 2018: Polymer-augmented liposomes enhancing antibiotic delivery against intracellular infections., Biomater Sci, 6, p. 1976, DOI: 10.1039/C8BM00282G 153 10.1039/C8BM00282G false true Reference 56065794 /api/reference/56065794 154. Kalhapure 2017: Enhancing targeted antibiotic therapy via pH responsive solid lipid nanoparticles from an acid cleavable lipid., Nanomedicine, 13, p. 2067, DOI: 10.1016/j.nano.2017.04.010 154 10.1016/j.nano.2017.04.010 false true Reference 56065795 /api/reference/56065795 155. Omolo 2021: Liposomes with pH responsive ‘on and off’switches for targeted and intracellular delivery of antibiotics., J Liposome Res, 31, p. 45, DOI: 10.1080/08982104.2019.1686517 155 10.1080/08982104.2019.1686517 false true Reference 56065796 /api/reference/56065796 156. Makhathini 2019: Novel two-chain fatty acid-based lipids for development of vancomycin pH-responsive liposomes against Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA)., J Drug Target, 27, p. 1094, DOI: 10.1080/1061186X.2019.1599380 156 10.1080/1061186X.2019.1599380 false true Reference 56065797 /api/reference/56065797 157. Zhentan 2013: pH-triggered hydrogel degradation for the smart release of antibiotic aiming at bacterial infection., Communication, 13, p. 1 157 false true Reference 56065798 /api/reference/56065798 158. Osman 2019: Novel fatty acid-based pH-responsive nanostructured lipid carriers for enhancing antibacterial delivery., J Drug Deliv Sci Technol, 53, p. 101125, DOI: 10.1016/j.jddst.2019.101125 158 10.1016/j.jddst.2019.101125 false true Reference 56065799 /api/reference/56065799 159. Maji 2019: pH-responsive lipid-dendrimer hybrid nanoparticles: An approach to target and eliminate intracellular pathogens., Mol Pharmaceutics, 16, p. 4594, DOI: 10.1021/acs.molpharmaceut.9b00713 159 10.1021/acs.molpharmaceut.9b00713 false true Reference 56065800 /api/reference/56065800 160. Daniel 2020: Novel chitosan-based pH-responsive lipid-polymer hybrid nanovesicles (OLA-LPHVs) for delivery of vancomycin against methicillin-resistant Staphylococcus aureus infections., Biol Macromol, 10, p. 1 160 false true Reference 56065801 /api/reference/56065801 161. Qu 2018: Injectable antibacterial conductive hydrogels with dual response to an electric field and pH for localized “smart” drug release., Acta Biomater, 72, p. 55, DOI: 10.1016/j.actbio.2018.03.018 161 10.1016/j.actbio.2018.03.018 false true Reference 56065802 /api/reference/56065802 162. Seetharaman 2017: Design, preparation and characterization of pH-responsive prodrug micelles with hydrolyzable anhydride linkages for controlled drug delivery., J Colloid Interface Sci, 492, p. 61, DOI: 10.1016/j.jcis.2016.12.070 162 10.1016/j.jcis.2016.12.070 false true Reference 56065803 /api/reference/56065803 163. Zeng 2020: Indomethacin-grafted and pH-sensitive dextran micelles for overcoming inflammation-mediated multidrug resistance in breast cancer., Carbohydr Polym, 237, p. 116139, DOI: 10.1016/j.carbpol.2020.116139 163 10.1016/j.carbpol.2020.116139 false true Reference 56065804 /api/reference/56065804 164. Wersig 2017: Poly (glycerol adipate)-indomethacin drug conjugates-synthesis and in vitro characterization., Int J Pharm, 531, p. 225, DOI: 10.1016/j.ijpharm.2017.08.093 164 10.1016/j.ijpharm.2017.08.093 false true Reference 56065805 /api/reference/56065805 165. Xu 2020: Modular acid-activatable acetone-based ketal-linked nanomedicine by dexamethasone prodrugs for enhanced anti-rheumatoid arthritis with low side effects., Nano Lett, 20, p. 2558, DOI: 10.1021/acs.nanolett.9b05340 165 10.1021/acs.nanolett.9b05340 false true Reference 56065806 /api/reference/56065806 166. Su 2021: Therapeutic effect of pH-Responsive dexamethasone prodrug nanoparticles on acute lung injury., J Drug Deliv Sci Technol, 66, p. 102738, DOI: 10.1016/j.jddst.2021.102738 166 10.1016/j.jddst.2021.102738 false true Reference 56065807 /api/reference/56065807 167. Alam 2017: Endogenous inspired biomineral-installed hyaluronan nanoparticles as pH-responsive carrier of methotrexate for rheumatoid arthritis., J Control Release, 252, p. 62, DOI: 10.1016/j.jconrel.2017.03.012 167 10.1016/j.jconrel.2017.03.012 false true Reference 56065808 /api/reference/56065808 168. Zhang 2023: Hyaluronic acid-based prodrug nanomedicines for enhanced tumor targeting and therapy: A review., Int J Biol Macromol, 249, p. 125993, DOI: 10.1016/j.ijbiomac.2023.125993 168 10.1016/j.ijbiomac.2023.125993 false true Reference 56065809 /api/reference/56065809 169. Shin 2014: A hyaluronic acid–methotrexate conjugate for targeted therapy of rheumatoid arthritis., Chem comm, 50, p. 7632, DOI: 10.1039/c4cc02595d 169 10.1039/c4cc02595d false true Reference 56065810 /api/reference/56065810 170. Lee 2018: Inflammation-responsive drug-conjugated dextran nanoparticles enhance anti-inflammatory drug efficacy., ACS Appl Mater Interfaces, 10, p. 40378, DOI: 10.1021/acsami.8b08254 170 10.1021/acsami.8b08254 false true Reference 56065811 /api/reference/56065811 171. Li 2017: pH-sensitive polymeric micelles for targeted delivery to inflamed joints., J Control Release, 246, p. 133, DOI: 10.1016/j.jconrel.2016.12.027 171 10.1016/j.jconrel.2016.12.027 false true Reference 56065812 /api/reference/56065812 172. Zhang 2019: pH-responsive nanoparticles targeted to lungs for improved therapy of acute lung inflammation/injury., ACS Appl Mater Interfaces, 11, p. 16380, DOI: 10.1021/acsami.9b04051 172 10.1021/acsami.9b04051 false true Reference 56065813 /api/reference/56065813 173. Lei 2021: Narrow pH response multilayer films with controlled release of ibuprofen on magnesium alloy., Mater Sci Eng C, 118, p. 111414, DOI: 10.1016/j.msec.2020.111414 173 10.1016/j.msec.2020.111414 false true Reference 56065814 /api/reference/56065814 174. Aldayel 2016: Acid-sensitive sheddable PEGylated PLGA nanoparticles increase the delivery of TNF-α siRNA in chronic inflammation sites., Mol Ther Nucleic Acids, 5, p. 340, DOI: 10.1038/mtna.2016.39 174 10.1038/mtna.2016.39 false true Reference 56065815 /api/reference/56065815 175. O’Mary 2017: Acid-sensitive sheddable PEGylated, mannose-modified nanoparticles increase the delivery of betamethasone to chronic inflammation sites in a mouse model., Mol Pharmaceutics, 14, p. 1929, DOI: 10.1021/acs.molpharmaceut.7b00024 175 10.1021/acs.molpharmaceut.7b00024 false true Reference 56065816 /api/reference/56065816 176. Zhao 2017: Multifunctional folate receptor-targeting and pH-responsive nanocarriers loaded with methotrexate for treatment of rheumatoid arthritis., Int J Nanomedicine, 12, p. 6735, DOI: 10.2147/IJN.S140992 176 10.2147/IJN.S140992 false true Reference 56065817 /api/reference/56065817 177. Zhang 2020: A pH/ROS dual-responsive and targeting nanotherapy for vascular inflammatory diseases., Biomaterials, 230, p. 119605, DOI: 10.1016/j.biomaterials.2019.119605 177 10.1016/j.biomaterials.2019.119605 false true Reference 56065818 /api/reference/56065818 178. Sun 2021: Teng L Self-assembled pH-sensitive polymeric nanoparticles for the inflammation-targeted delivery of Cu/Zn-superoxide dismutase., ACS Appl Mater Interfaces, 13, p. 18152, DOI: 10.1021/acsami.1c03589 178 10.1021/acsami.1c03589 false true Reference 56065819 /api/reference/56065819 179. Liu 2018: Multifunctional nanohybrid based on porous silicon nanoparticles, gold nanoparticles, and acetalated dextran for liver regeneration and acute liver failure theranostics., Adv Mater, 30, p. 1703393, DOI: 10.1002/adma.201703393 179 10.1002/adma.201703393 false true Reference 56065820 /api/reference/56065820 180. Liu 2008: Synthesis and evaluation of a well-defined HPMA copolymer-dexamethasone conjugate for effective treatment of rheumatoid arthritis., Pharm Res, 25, p. 2910, DOI: 10.1007/s11095-008-9683-3 180 10.1007/s11095-008-9683-3 false true Reference 56065821 /api/reference/56065821 181. Liu 2010: Syntheses of click PEG- dexamethasone conjugates for the treatment of rheumatoid arthritis., Biomacromolecules, 11, p. 262, DOI: 10.1021/bm100578c 181 10.1021/bm100578c false true Reference 56065822 /api/reference/56065822 182. Zhu 2015: pH‐responsive drug‐delivery systems., Chem Asian J, 10, p. 284, DOI: 10.1002/asia.201402715 182 10.1002/asia.201402715 false true Reference 56065823 /api/reference/56065823 183. Schattling 2014: Multi-stimuli responsive polymers-the all-in-one talents., Polym Chem, 5, p. 25, DOI: 10.1039/C3PY00880K 183 10.1039/C3PY00880K false true Reference 56065824 /api/reference/56065824 184. Tang 2010: Water‐soluble triply‐responsive homopolymers of N, N‐dimethylaminoethyl methacrylate with a terminal azobenzene moiety., J Polym Sci Part A: Polym Chem, 48, p. 2564, DOI: 10.1002/pola.24034 184 10.1002/pola.24034 false true Reference 56065825 /api/reference/56065825 185. Sonawane 2017: Hydrazone linkages in pH responsive drug delivery systems., Eur J Pharm Sci, 99, p. 45, DOI: 10.1016/j.ejps.2016.12.011 185 10.1016/j.ejps.2016.12.011 false true Reference 56065826 /api/reference/56065826 186. Li 2015: On-demand combinational delivery of curcumin and doxorubicin via a pH-labile micellar nanocarrier., Int J Pharm, 495, p. 572, DOI: 10.1016/j.ijpharm.2015.09.022 186 10.1016/j.ijpharm.2015.09.022 false true Reference 56065827 /api/reference/56065827 187. Wang 2015: Tuning the architecture of polymeric conjugate to mediate intracellular delivery of pleiotropic curcumin., Eur J Pharm Biopharm, 90, p. 53, DOI: 10.1016/j.ejpb.2014.11.002 187 10.1016/j.ejpb.2014.11.002 false true Reference 56065828 /api/reference/56065828 188. Su 2016: Polymeric complex micelles based on the double-hydrazone linkage and dual drug-loading strategy for pH-sensitive docetaxel delivery., J Mater Chem B, 4, p. 1122, DOI: 10.1039/C5TB02188J 188 10.1039/C5TB02188J false true Reference 56065829 /api/reference/56065829 189. Aryal 2010: Polymer-cisplatin conjugate nanoparticles for acid-responsive drug delivery., ACS nano, 4, p. 251, DOI: 10.1021/nn9014032 189 10.1021/nn9014032 false true Reference 56065830 /api/reference/56065830 190. Alani 2010: Polymeric micelles for the pH-dependent controlled, continuous low dose release of paclitaxel., Biomaterials, 31, p. 1765, DOI: 10.1016/j.biomaterials.2009.11.038 190 10.1016/j.biomaterials.2009.11.038 false true Reference 56065831 /api/reference/56065831 191. Varkouhi 2011: Endosomal escape pathways for delivery of biologicals., J Control Release, 151, p. 220, DOI: 10.1016/j.jconrel.2010.11.004 191 10.1016/j.jconrel.2010.11.004 false true /api/publication/35149394 Nazli Adila et al. Acid-sensitive Prodrugs; A Promising Approach for Site-specific and Targeted Drug Release. (2024) EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 0223-5234 1768-3254 276<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10087515"><a href="/gui2/?type=authors&mode=browse&sel=10087515" target="_blank">Nazli Adila ✉ (<span class="authorship-author-name">Nazli Adila</span> <span class="authorAux-mtmt"> farmakognózia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Farmakognóziai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Irshad Khan Muhammad Zafar </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10020499"><a href="/gui2/?type=authors&mode=browse&sel=10020499" target="_blank">Rácz Ákos (<span class="authorship-author-name">Rácz Ákos</span> <span class="authorAux-mtmt"> molekula modellezés</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Farmakognóziai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10001293"><a href="/gui2/?type=authors&mode=browse&sel=10001293" target="_blank">Béni Szabolcs (<span class="authorship-author-name">Béni Szabolcs</span> <span class="authorAux-mtmt"> NMR-spektroszkópia, analitikai kémia</span>) </a> </span> <span class="author-affil"><span title="Eötvös Loránd Tudományegyetem">ELTE</span>/<span title="Természettudományi Kar">TTK</span>/<span title="Kémiai Intézet">KI</span>/Analitikai Kémiai Tanszék</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;35149394" target="_blank">Acid-sensitive Prodrugs; A Promising Approach for Site-specific and Targeted Drug Release</a></div> <div> <span class="journal-title">EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/0223-5234">0223-5234</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1768-3254">1768-3254</a>)</span>: <span class="journal-volume">276</span> <span class="page"> Paper 116699. 32 p. </span> <span class="year">(2024)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.1016/j.ejmech.2024.116699" target="_blank" href="https://doi.org/10.1016/j.ejmech.2024.116699"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001285946300001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001285946300001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85199955394" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85199955394"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="39089000" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39089000&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Drug Discovery&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Medicine (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Organic Chemistry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Pharmacology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 31</span> | Független: 31 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 28 | Scopus jelölt:&nbsp;23 | WoS/Scopus jelölt:&nbsp;29 | DOI jelölt:&nbsp;31 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;35149394&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 1 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 35149394</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Összefoglaló cikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (SE250+ Excellence Scholarship for PhD Students) </div> <div class="lastModified">Utolsó módosítás: 2024.08.16. 09:29 Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Department of Pharmacognosy, Semmelweis University, Budapest, 1085, Hungary College of Pharmaceutical Sciences, Zhejiang University, Zhejiang, Hangzhou, 310058, China Integrative Health and Environmental Analysis Research Laboratory, Department of Analytical Chemistry, Institute of Chemistry, Eötvös Loránd University, Budapest, 1117, Hungary ...</pre> </div></div>